重组抗人HLA-DR单抗(L243) | Syd Labs PA007453
体内实验级重组抗人HLA-DR单克隆抗体，小鼠IgG2a Kappa(克隆号L243，Syd Labs货号：PA007453)，适用于体外和体内研究，纯度>95%。其不变区为小鼠Mouse IgG2a Kappa (mIgG2a或m2a)，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007453 |
|---|---|
| 产品名称 | 重组抗人HLA-DR单抗(L243) | Syd Labs PA007453 |
| 英文名 | In vivo Grade Recombinant Anti-Human HLA-DR Monoclonal Antibody, Mouse IgG2a Kappa (Clone: L243) |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | DRA/DRB1、HLA II类组织相容性抗原DRα/DRB1-15β链、HLA-DRA1/DRB1、MHC II类抗原DRA |
| 概述 | Syd Labs提供重组小鼠IgG2a同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | L243 |
| 同种型 | 小鼠 IgG2a kappa |
| 应用 | ELISA、流式细胞术、中和、功能测定，如生物分析PK和ADA测定，以及用于研究受人HLA-DR蛋白影响的生物途径的测定。 |
| 免疫源 | 抗人HLA-DR单克隆抗体（克隆：L243）在哺乳动物细胞中产生 |
| 抗体形式 | 0.2 μM过滤溶液，1x PBS |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗人HLA-DR单克隆抗体 ，小鼠IgG2a Kappa(克隆号L243)用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 1 个月，保存在2 至 8°C。 自收到之日起12个月，保存在-20 至 -70°C。 |
| 注意事项 | PA007453 Syd Labs提供重组小鼠IgG2a同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA、流式细胞术、中和、功能测定，如生物分析PK和ADA测定，以及用于研究受人HLA-DR蛋白影响的生物途径的测定。 |
文献
抗人HLA-DR单克隆抗体，体内实验级重组，小鼠IgG2a Kappa(克隆号L243)（In vivo Grade Recombinant Anti-Human HLA-DR Monoclonal Antibody, Mouse IgG2a Kappa (Clone: L243)，货号：PA007453 Syd Labs）
抗人HLA-DR单抗(L243)部分引用文献:
1. Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity
Brentville, V. A., et al. Cancer Res. 2016 Feb 1;76(3):548-60. PMID: 26719533
“To construct the plasmid pVitro 2 Chimeric HLA-DR401, cDNA was generated from mRNA isolated from the splenocytes of transgenic HLA-DR4 mice. …Following sequence confirmation full-length chimeric alpha chain comprising murine H2-Ea with the human HLA-DRA alpha 1 domain was ligated into the FspI/EcoRI mcs2 of the vector pVITRO2-hygro-mcs (Invivogen). …To generate the IFNgamma-inducible plasmid pDCGAS chimeric HLA-DR401, the chimeric alpha and beta chains, were cloned into the pDCOrig vector described elsewhere (24) in replacement of the heavy and light chain. …The CMV promoter within each cassette was excised and replaced with the IFNgamma-inducible promoter driving expression of the HLA-DR401 chains within the pDCOrig vector backbone. …For MHC blocking studies 20 microg/mL of the HLA-DR (clone L243)-specific antibody was added to Elispot assays.”
2. The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01
Hirasawa, M., et al. PLoS One. 2015 Jun 22;10(6):e0130928. PMID: 26098642
“Although the expressions of these two alleles are highly correlated, comparisons of HLA-DR and HLA-DQ heterodimer protein pairing suggested the HLA-DRB1*07:01 allele provided the simplest causal association with lapatinib-induced ALT elevation. …In this study, we evaluated the effect of lapatinib on the binding of the known ligand peptides to HLA-DRB1*07:01 and DRB1*15:01 in vitro. …Also we performed a series of in silico molecular modeling for HLA-DRB1*07:01 and two other HLA-DRs to further assess the possible role of lapatinib on HLA-peptide binding, which could lead to the mechanism of immune-mediated lapatinib-induced liver injury. …The finding motivated us to predict the possible interaction mode of lapatinib with HLA-DRs. …In summary, our in vitro experiments revealed that lapatinib enhances binding of the ligand peptide to HLA-DRB1*07:01 preferentially.”
3. Preserved dendritic cell HLA-DR expression and reduced regulatory T cell activation in asymptomatic Plasmodium falciparum and P. vivax infection
Kho, S., et al. Infect Immun. 2015 Aug;83(8):3224-32. PMID: 26034211
“Peripheral blood total DC were identified by flow cytometry as lineage marker-negative HLA-DR+ cells. …The activation/maturation of circulating blood DC was examined by measuring the median fluorescence intensity of HLA-DR expression. …In a limited number of samples, additional staining was possible and HLA-DR expression could be examined on two myeloid DC (mDC) subsets, CD1c+ (blood dendritic cell antigen 1 [BDCA-1] positive) mDC (CD1c+ mDC) and CD141+ (BDCA-3 positive) mDC (CD141+ mDC). …In both mDC subsets, HLA-DR was preserved during asymptomatic infection, but in 3 adults with uncomplicated malaria, HLA-DR expression appeared reduced. …Total DC HLA-DR expression was inversely correlated with parasitemia in adults with asymptomatic P. falciparum infection (rs = -0.54, P = 0.02, n = 18) and positively correlated in children with asymptomatic P. vivax infection (rs = 0.80, P = 0.01, n = 9).”
4. Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation
Esser, M. T., et al. J Virol. 2001 Jul;75(13):6173-82. PMID: 11390619
“The HIV virion envelope is enriched for HLA-DR but not DP or DQ (2, 6, 18, 45), and virion-associated MHC-II can bind and present the superantigen Staphylococcus enterotoxin B to resting T cells, resulting in T-cell activation. …Immunofluorescent staining of PBMC and MDMs (3 x 10^5 per condition) was performed at 4 degree C for 30 min by using isotype immunoglobulin G1 (IgG1) (X40), IgG2a (X39), and V4 (non-gp120-interacting domain on CD4) and HLA-DR (L243) MAbs from Becton Dickinson Immunocytometry Systems (San Jose, Calif.). …The HLA-DR genotype of the T1, T2, TBLCL-CD4, and H9 cell lines; the phenotype of the virion envelope; and whether the HIV-1NL4-3-AT2 virions triggered cell death are summarized in Table. …Future studies will determine whether the HLA-DR phenotype of the virus or the responder PBMC affects HIV-1-triggered apoptosis. …We thank Mike Grimes and Bill Bohn for the production and characterization of sucrose-banded, purified HIV-1NL4-3, Antonio Valentin and Jim Turpin for the generous gifts of selected HIV-1 isolates, and Darlene Marti and Mary Carrington for HLA-DR genotyping of the PBMC donor and cell lines.”